Advertisement

Lymphocyte Subpopulations and Tumor Necrosis Factor During Interferon-α 2b and Interleukin-2 Therapy in Patients with Metastasized Renal Cell Cancer

  • A. Manseck
  • B. Mansouri Taleghani
  • M. Wirth
Conference paper

Abstract

Treatment of patients with metastasized renal cell cancer with interferon-α2b (IFN-α2b) and interleukin-2 (IL-2) initially led to a drop in the total lymphocyte count and in all lymphocyte subpopulations with the exception of CD-19-positive cells. Upon termination of therapy, there was an excessive increase in all lymphocyte subpopulations. No correlation between the kinetics of the lymphocyte subpopulations and the clinical outcome of the patient was demonstrated. Significant stimulation of tumor necrosis factor-α (TNF-α) as a result of the treatment was not detected. This may indicate that stimulation of TNF-α by IL-2 is not an important effector mechanism.

Keywords

Renal Cell Carcinoma Lymphocyte Subpopulation Advanced Renal Cell Carcinoma Total Lymphocyte Count Human Renal Cancer Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ackermann R (1988) Immunologische Aspekte in der Behandlung des Nierenkarzinoms. In: Staehler G (ed) Das Nierenkarzinom. Springer, Berlin Heidelberg New York Tokyo, S 104–114.Google Scholar
  2. 2.
    Atzpodien J (1990) Home therapy with recombinant interleukin-2 and interferon-α 2b in advanced human malignancies. Lancet 335:1509–1512.PubMedCrossRefGoogle Scholar
  3. 3.
    Blay JY et al (1990) Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor. Cancer Res 50:2371–2374.PubMedGoogle Scholar
  4. 4.
    Bono AV (1986) Steroid hormones and hormonal treatment in renal cell carcinoma. In: DeKernion JB, Pavone Macaluso M (eds) Tumors of the kidney, vol 13. Williams & Wilkins, Baltimore, pp 205–227.Google Scholar
  5. 5.
    Budd TJ et al (1989) Phase I clinical trial of interleukin-2 and α-interferon: toxicity and immunologic effects. Cancer Res 49:6432–6436.PubMedGoogle Scholar
  6. 6.
    DeKernion JB (1986) Treatment of advanced renal cell carcinoma. Traditional methods and innovative approaches. J Urol 130:2–7.Google Scholar
  7. 7.
    Dinarelle CA, Mier JW (1986) Interleukins. Ann Rev Med 37:173–178.CrossRefGoogle Scholar
  8. 8.
    Domzig W et al (1983) Interleukin-2 dependence of human natural killer (NK) cell activity. J Immunol 130:1970–1973.PubMedGoogle Scholar
  9. 9.
    Fowler JE (1986) Failure of immunotherapy for metastatic renal cell carcinoma. J Urol 135:22–25.PubMedGoogle Scholar
  10. 10.
    Grimm EA et al (1982) Lymphokine-activated killer cell phenomenon. JExpMed 155:1823–1841.CrossRefGoogle Scholar
  11. 11.
    Gumlo BT et al (1988) Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine activated killer cells. Cancer Res 48:5864–5867.Google Scholar
  12. 12.
    Hefeneider SH et al (1983) In vivo interleukin-2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident killer cells. J Immunol 130:222–227.PubMedGoogle Scholar
  13. 13.
    Kriegmair M, Hofstetter A (1989) Interferontherapie in der Urologie. Urologe [A] 28:116–121.Google Scholar
  14. 14.
    Krown SE (1987) Interferon treatment of renal cell carcinoma. Cancer 59 [Suppl]:647–651.PubMedCrossRefGoogle Scholar
  15. 15.
    Marumo K et al (1989) Immunologic study of human recombinant interleukin-2 (low-dose) in patients with advanced renal cell carcinoma. Urology 33:219–225.PubMedCrossRefGoogle Scholar
  16. 16.
    Mier JW et al (1988) Induction of circulating tumor necrosis factor (TNF-α) as the mechanism of the febrile response to IL-2 in our patients. J Clin Immunol 82:426–436.CrossRefGoogle Scholar
  17. 17.
    Miltenburg AMM et al (1988) Lymphokine-activated killer cells lyse human renal cancer cell lines and cultured normal kidney cells. Immunology 63:729–731.PubMedGoogle Scholar
  18. 18.
    Neidhard JA et al (1984) Interferon-α therapy of renal cancer. Cancer Res 44:4140–4143.Google Scholar
  19. 19.
    Otto U et al (1988) Die Behandlung des metastasierten Nierenkarzinoms mit rekombinantem α-2-oder γ-Interferon. Onkologie 11:185–194.PubMedCrossRefGoogle Scholar
  20. 20.
    Reem GH, Yeh NH (1984) Interleukin-2 regulates expression of its receptors and synthesis of γinterferon by human T lymphocytes. Science 225:429–430.PubMedCrossRefGoogle Scholar
  21. 21.
    Rosenberg SA et al (1989) Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863–1874.PubMedGoogle Scholar
  22. 22.
    Urba WJ et al (1990) Immunomodulatory properties and toxicity of interleukin-2 in patients with cancer. Cancer Res 50:185–192.PubMedCrossRefGoogle Scholar
  23. 23.
    West WH et al (1987) Constant infusion of recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • A. Manseck
    • 1
  • B. Mansouri Taleghani
    • 2
  • M. Wirth
    • 1
  1. 1.Urologische Klinik und Poliklinik der UniversitätWürzburgGermany
  2. 2.Medizinische Klinik, Hämatologie der UniversitätWürzburgGermany

Personalised recommendations